Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Study acronym: SURF201
StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Sep 2026 → Mar 2027
See other at-risk trials from Tyra Biosciences, Inc

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 2026 to Mar 2027
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 2 of 11 entries
  2. Enrollment closed, study ongoing
    • Site details revised at 4 of 4 sites
    v8
  3. 2 versions Re-verified since Oct 1, 2024, no change to tracked fieldsv6-v7
  4. Site contacts updated at 2 of 4 sitesv5
  5. Study sites: 3 to 4v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 2 to 3v3
  2. Study sites: 1 to 2v2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
Trial Details
NCT Number NCT06160752
Lead Sponsor Tyra Biosciences, Inc
Conditions
(from sponsor)		 Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Related terms Acrocephalosyndactylia, Cholangiocarcinoma, Neoplasm Metastasis
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov